Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 609-615

  Kaudewitz, Dorothee ^a   Lee, Regent ^b   Willeit, Peter ^a,c   McGregor, Reuben ^a   Markus, Hugh S ^d   Kiechl, Stefan ^e   Zampetaki, Anna ^a   Storey, Robert F ^f   Channon, Keith M ^b   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cardiology; Clinical trials; Coronary syndrome; Heparins

Indexed keywords

HEPARIN; MICRORNA;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CAENORHABDITIS ELEGANS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART CATHETERIZATION; HUMAN; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; ANIMALS; ANTICOAGULANTS; BLOOD PLATELETS; CAENORHABDITIS ELEGANS; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICRORNAS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84883248332     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0368     Document Type: Article

References (34)

1. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101: 1225-1236.
2. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103: 919-928.
3. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
4. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 27-33.
5. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma MicroRNA profiling reveals loss of endothelial MiR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
6. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-433.
7. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008.
8. Mayr M, Zampetaki A, Willeit P, et al. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol 2013; 33: 206-214.
9. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.
10. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res 2012; 110: 508-522.
11. de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; in press.
12. Cavarretta E, Chiariello GA, Condorelli G. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur Heart J 2013; in press.
13. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112: 595-600.
14. Curtis AM, FitzGerald GA. Platelet microRNAs: Novy Mir* or mired in human complexity? Circ Res 2013; 112: 576-578.
15. Lee R, Antonopoulos AS, Alexopoulou Z, et al. Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease. Int J Cardiol 2013; in press.
16. Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating MiRNAs. Thromb Haemost 2012; 108: 592-598.
17. Boeckel JN, Thome CE, Leistner D, et al. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem 2013; in press
18. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006; 113: 1871-1878.
19. Lee R, Adlam D, Antoniades C, et al. Heparin administration leads to rapid decrease in plasma matrix metalloproteinase-9. Int J Cardiol 2013; 163: 212-213.
20. Zampetaki A, Willeit P, Drozdov I, et al. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93: 555-562.
21. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391-412.
22. Yokota M, Tatsumi N, Nathalang O, et al. Effects of heparin on polymerase chain reaction for blood white cells. J Clin Lab Anal 1999; 13: 133-140.
23. Satsangi J, Jewell DP, Welsh K, et al. Effect of heparin on polymerase chain reaction. Lancet 1994; 343: 1509-1510.
24. Neuhoff V, Schill WB, Sternbach H. Micro-analysis of pure deoxyribonucleic acid-dependent ribonucleic acid polymerase from Escherichia coli. Action of heparin and rifampicin on structure and function. Biochem J 1970; 117: 623-631.
25. Chen JZ, Herzenberg LA, Herzenberg LA. Heparin inhibits EcoRI endonuclease cleavage of DNA at certain EcoRI sites. Nucleic Acids Res 1990; 18: 3255-3260.
26. Lazarus LH, Kitron N. Inhibition and dissociation of mammalian polymeric DNA polymerase by heparin. Arch Biochem Biophys 1974; 164: 414-419.
27. Shen X, Fang J, Lv X, et al. Heparin impairs angiogenesis through inhibition of microRNA-10b. J Biol Chem 2011; 286: 26616-26627.
28. Izraeli S, Pfleiderer C, Lion T. Detection of gene expression by PCR amplification of RNA derived from frozen heparinized whole blood. Nucleic Acids Res 1991; 19: 6051.
29. Tsai M, Miyamoto M, Tam SY, et al. Detection of mouse mast cell-associated protease mRNA. Heparinase treatment greatly improves RT-PCR of tissues containing mast cell heparin. Am J Pathol 1995; 146: 335-343.
30. Ding M, Bullotta A, Caruso L, et al. An optimized sensitive method for quantitation of DNA/RNA viruses in heparinized and cryopreserved plasma. J Virol Methods 2011; 176: 1-8.
31. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-875.
32. Oerlemans MI, Mosterd A, Dekker MS, et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med 2012; 4: 1176-1185.
33. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 499-506.
34. Gao W, He HW, Wang ZM, et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 2012; 11: 55.